Starlink is expanding into Vietnam with a focus on improving healthcare connectivity.The goal: enable telemedicine, remote consultations, and digital health infrastructure. https://t.co/zVYfzTycQo ...

[Applause] [Music] Hi, I'm Rose Bianini. Um, and today I'm talking about something that is universal yet we avoid talking about which is the way we die. I want to re-imag care to ensure that all of us have what we would consider a good death.We all die. Everyone in this room is going to die. Our loved ones will die.Yet, it's something we don't talk about and we don't prepare for. When Canadians were asked, 96% of them understood that it was important to have some kind of end of life care wishes documented. ...

OMEGA HEALTHCARE INVESTORS INVESTOR PRESENTATION • This presentation may include projections and other "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements relate to future events and expectations and involve unknown risks and uncertainties. Omega's actual results or actions may differ materially from those projected in the forward-looking statements. For a summary of the specific risk factors that could cause results to differ materially f ...

Core Insights - GE HealthCare (GEHC) introduced Flyrcado, an FDA-approved PET imaging agent for myocardial perfusion imaging, at the 2025 SNMMI annual meeting, highlighting its importance in precision cardiac care as cardiovascular disease rates rise globally [1][8] - Flyrcado aims to enhance early disease detection, personalize treatment strategies, and monitor therapy responses, reinforcing GEHC's commitment to improving outcomes for patients at risk of cardiovascular disease [2][6] Product Details - Flyrcado (flurpiridaz F 18) is designed for patients with known or suspected coronary artery disease, featuring a half-life of approximately 110 minutes, which facilitates centralized production and distribution [3] - The agent integrates exercise stress testing with cardiac PET imaging and is compatible with GEHC's Omni Legend PET/CT and other systems, enabling detailed assessments of myocardial perfusion and related conditions [3] Market Position and Coverage - Flyrcado has recently launched in select U.S. markets, receiving CMS pass-through status and a specific HCPCS billing code, with coverage from all seven Medicare Administrative Contractors and over 50% of commercial insurers [4][8] - The expansion of coverage beyond hospital outpatient settings and the establishment of a Flyrcado Support Center for providers indicate a strategic move to enhance accessibility and support for the new imaging agent [4] Financial Performance and Stock Trends - Following the announcement, GEHC shares closed flat at $71.16, with a year-to-date decline of 9%, contrasting with the industry's 4% growth and the S&P 500's 0.8% increase [5][7] - GEHC's market capitalization stands at $32.64 billion, and the company reported a 10.9% earnings surprise in the last quarter, indicating potential for future growth despite current stock performance [7] Strategic Implications - Flyrcado positions GEHC for long-term growth in the high-value molecular imaging market, addressing the rising demand for precision cardiac diagnostics [6] - With broad payer coverage and compatibility with existing systems, Flyrcado is expected to facilitate a shift from SPECT to PET imaging, generating recurring revenue from both radiopharmaceutical sales and imaging hardware [6]

[Music] Hi. Hello. Bonjour. Hold on. Hold on. I'm good. I'm good. I think I just peed myself a little bit, but let's not make it weird. Um, I will say this, my body has impeccable timing, obviously, which you'll understand. This is very coherent with what's about to come. Um, I am here before you today, not as an expert, but as somebody surviving the messiness of midlife. So, it's the wear your PJs kind of messiness in case lunch break was adult for we can all take a quick nap, which it turned out not to be ...

Key Takeaways PFE expects steady 2025 COVID sales but anticipates major LOE losses and IRA headwinds in the future. Medicare Part D changes may cut into sales of key PFE drugs like Vyndaqel, Ibrance, Xtandi and Xeljanz. PFE trades at 7.82x forward earnings, below industry average, with EPS estimates rising for 2025 and 2026.Pfizer (PFE) is likely to encounter several headwinds in the next couple of years that can hurt its sales and profits, the first being declining sales of COVID products, Comirnaty and ...

Each of the 350+ businesses are run independently encompassing services delivered by more than 50,500 employees. We foster an entrepreneurial culture of ownership coupled with a field-driven, flat structure. Our independent subsidiaries offer a broad spectrum of post-acute care including skilled nursing, senior living, ancillary businesses and healthcare- related properties. E N S I G N G R O U P INVESTOR PRESENTATION M a y 2 0 2 5 w w w . e n s i g n g r o u p . n e t Table Of Contents Portfolio Our Servic ...

Core Insights - Fresenius Medical Care (FMS) has launched the "FME Reignite" strategy aimed at achieving industry-leading profitability while optimizing capital structure and advancing innovation in renal care [1][7] - The strategy includes a significant expansion of the FME25 program, now called FME25+, targeting €1.05 billion in sustainable cost savings by 2027, which is a €300 million increase from previous goals [2] - The establishment of Value-Based Care (VBC) as a standalone segment is expected to enhance transparency and contribute to growth, having generated €1.8 billion in revenues in 2024 [3] Profitability and Operational Focus - The FME25+ program focuses on operational excellence and margin expansion, aiming for mid-teens operating income margin by 2030 across Care Delivery and Care Enablement segments [2] - The program enhances scalability, standardization, and efficiency across clinics and manufacturing sites, leveraging synergies to streamline service delivery while maintaining care quality [4] Capital Structure and Shareholder Value - A new capital allocation framework aims to balance reinvestment and shareholder returns, with plans to allocate €800 million to €1 billion annually for capital expenditures through 2030 [5][8] - Fresenius will initiate a €1 billion share buyback program over two years starting in 2025 and has committed to a dividend payout ratio of 30-40% [8] Technological Advancements - The upcoming U.S. launch of the 5008X CAREsystem, a next-generation dialysis machine, is a cornerstone of the strategy, expected to improve clinical outcomes and operational efficiencies [10][11] - The 5008X system has shown a 4.4% mortality reduction over 2.5 years compared to conventional hemodialysis, promising lower hospitalization rates and improved treatment consistency [10] Competitive Positioning - Through the FME Reignite strategy, Fresenius is positioning itself as a financially disciplined, innovation-driven, and patient-centered leader in renal care, combining cost control with growth investments [12] - Compared to competitors like Baxter International, DaVita Inc., and Outset Medical, Fresenius has outperformed in share price, with a 19.8% increase year-to-date against the industry's decline of 12% [17]

High quality, highly accessible healthcare For all © 2 0 2 5 A l l R i g h t s R e s e r ve d – D oc Go Disclaimer This presentation is being delivered solely for informational purposes. No representation or warranty, express or implied, is made by DocGo, its affiliates, or any of their respective directors, officers, shareholders, members, partners or representatives as to the accuracy or completeness of any information in this presentation. Except where otherwise indicated, this presentation speaks as of ...

Core Insights - InnovAge sponsors the PBS documentary "Caregiving," which highlights the challenges faced by caregivers in America, featuring Bradley Cooper and narrated by Uzo Aduba [1][2] - The documentary aims to raise national awareness about the caregiving crisis, showcasing stories of families dealing with funding cuts, policy changes, and workforce issues [2] - InnovAge's mission focuses on supporting seniors and their caregivers through its PACE model, allowing older adults to age independently at home while providing dignity and autonomy [3] Company Overview - InnovAge is the largest provider of the Program of All-Inclusive Care for the Elderly (PACE) in the U.S., serving approximately 7,530 participants across 20 centers in six states as of March 31, 2025 [3] - The company aims to improve the quality of care for high-cost, frail seniors while reducing the over-utilization of expensive care settings [3] - InnovAge's person-centered care model is designed to benefit all stakeholders, including participants, families, providers, and government payors [3]